Antiangiogenic agents for the treatment of nonsmall cell lung cancer: Characterizing the molecular basis for serious adverse events

Cancer Investigation

Volumn 29, Issue 7, 2011, Pages 460-471

  Wu, Shenhong ^a   Keresztes, Roger S ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Angiogenesis; Biologic therapy; Lung cancer

Indexed keywords

AFLIBERCEPT; AMINOTRANSFERASE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; GEMCITABINE; INTEDANIB; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; PREDNISONE; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; VANDETANIB; VASCULOTROPIN;

ADD ON THERAPY; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANTIANGIOGENIC ACTIVITY; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; GLIOBLASTOMA; HUMAN; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEINURIA; RECURRENT CANCER; SIDE EFFECT; TREATMENT PLANNING; TREATMENT RESPONSE; VEIN THROMBOSIS; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BENZENESULFONATES; BLOOD COAGULATION DISORDERS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; HYPERTENSION; INDOLES; INTESTINAL PERFORATION; LUNG NEOPLASMS; PROTEINURIA; PYRIDINES; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 79960165932     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.597815     Document Type: Article

References (98)

1. Jemal A, Siegel R, Xu J,Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86(3): 353-364. (Pubitemid 26272076)
3. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006;312(5777):1171-1175. (Pubitemid 43801134)
4. KreuterM, Kropff M, Fischaleck A, Junker K, Gerss J,Heinecke A, Lindermann M, Reinmuth N, Berdel WE, Mesters RM, Thomas M. Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatment. Eur Respir J 2009;33(6): 1383-1388.
5. Meert AP, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout JM, Lafitte JJ, Mascaux C, Sculier JP. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature withmeta-analysis. Br J Cancer 2002;87(7):694-701. (Pubitemid 35178743)
6. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995;147(1):9-19.
7. Folkman J, Klagsbrun M. Vascular physiology. A family of angiogenic peptides. Nature 1987;329(6141):671-672.
8. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267(16): 10931-10934.
9. Yuan A, Yu C-J,Kuo S-H, Chen,W-J, Lin F-Y, Luh,K-T, Yang P-C, Lee Y-C. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 2001;19(2):432-441. (Pubitemid 32112856)
10. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996;56(7):1615-1620. (Pubitemid 26104026)
11. Elice F, Rodeghiero F. Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. Thromb Res 2010;125(Suppl. 2):S55-S57.
12. Beitz JG, Kim IS, Calabresi P, Frackelton AR Jr. Human microvascular endothelial cells express receptors for platelet-derived growth factor. Proc Natl Acad Sci U S A 1991;88(5):2021-2025.
13. Pietras K, RubinK, SjoblomT, Buchdunger E, Sjoquist M, Heldin CH, Ostman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62(19):5476-5484.
14. Levitzki A. PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. Cytokine Growth Factor Rev 2004;15(4):229-235. (Pubitemid 38781048)
15. Murakami M, Zheng Y, Hirashima M, Suda T, Morita Y, Ooehara J, Ema H, Fong GH, Shibuya M. VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment. Arterioscler Thromb Vasc Biol 2008;28(4):658-664. (Pubitemid 351651323)
16. Kano MR, Morishita Y, Iwata C, Iwasaka S, Watabe T, Ouchi Y, Miyazono K, Miyazawa K. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci 2005;118(Pt. 16): 3759-3768. (Pubitemid 41309422)
17. Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, Funa K, Brakenhielm E, Cao Y. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 2007;117(10):2766-2777. (Pubitemid 47529608)
18. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111(9):1287-1295. (Pubitemid 36554699)
19. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survivalmechanisms. FASEB J 2004;18(2):338-340.
20. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8(4):299-309. (Pubitemid 41443415)
21. AVASTIN (bevacizumab). Solution for Intravenous Infusion [Package Insert]. South San Francisco, CA: Genentech, Inc., 2011.
22. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-2676.
23. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28(20):3239-3247.
24. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29(10):1252-1260.
25. Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM,MorrisMJ, Kantoff PW,Monk JP III, Small EJ, Cancer and LeukemiaGroup B.Arandomized, double-blind, placebocontrolled phase III trial comparing docetaxel, prednisone, and placebowith docetaxel, prednisone, and bevacizumab in menwith metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol 2010;28(18S):Abstract LBA4511.
26. Ocana A, Amir E, Vera F, Eisenhauer EA, Tannock IF. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol 2011;29(3):254-256.
27. Hapani S, Sher A, Chu D,Wu S. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010;79(1-2):27-38.
28. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300(19): 2277-2285.
29. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010;49(3):287-297.
30. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99(16):1232-1239. (Pubitemid 47299901)
31. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009;10(6):559-568.
32. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49(2):186-193. (Pubitemid 46178407)
33. Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010;21(8):1381-1389.
34. Mir O, Mouthon L, Alexandre J, Mallion JM, Deray G, Guillevin L, Goldwasser F. Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst 2007;99(1):85-86.
35. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertensionwith sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008;9(2):117-123.
36. Zhu X, Stergiopoulos K,Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009;48(1):9-17.
37. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62(16):4645-4655.
38. Lee J, Hirsh V, Park K, Qin S, Blajman CR, Perng R, Emerson L, Langmuir PB, Manegold C. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2010;28(15S):Abstract 7525.
39. De Boer R, Arrieta O, Gottfried M, Blackhall FH, Raats J, Yang CH, Langmuir P, Milenkova T, Read J, Vansteenkiste J. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). J Clin Oncol 2009;27(15S):Abstract 8010.
40. Herbst RS, Sun Y, EberhardtWE, Germonpre P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010;11(7):619-626.
41. Natale RB, Thongprasert S, Greco FA,Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Langmuir P, Rowbottom JA, Goss GD. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). J Clin Oncol 2009;27(15S):Abstract 8009.
42. AstraZeneca. AstraZeneca withdraws regulatory submissions for Zactima (vandetanib) in combination with chemotherapy for advanced NSCLC. Retrieved June 23, 2010, from http://www.astrazeneca.com/media/latest-press-releases/ zactima-adv-NSCLC?itemId = 7317146
43. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF III, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11):2184-2191. (Pubitemid 41095154)
44. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-2550. (Pubitemid 44917502)
45. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-smallcell lung cancer: AVAiL. J Clin Oncol 2009;27(8):1227-1234.
46. Faoro L, Hainsworth JD, Karlin DA, Huang JE, Fang L, Scappaticci FA. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab (BV) plus paclitaxel/carboplatin (PC) as first-line treatment (tx) for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(7S):Abstract 7583.
47. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, Akerley W. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009;27:5255-5261.
48. Wozniak AJ,Garst J, Jahanzeb M, KostyMP, Vidaver R, Beatty S, Teng S, Flick ED, Sing A, Lynch TJ, for the ARIES Investigators. Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): results from ARIES, a bevacizumab (BV) observational cohort study (OCS). J Clin Oncol 2010;28(7S):Abstract 7618.
49. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Dancy I, Spriggs DR, Tew WP. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010;28(2):207-214.
50. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099- 7109. (Pubitemid 39331023)
51. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrao Miziara JE, Balint B, de Marinis F, Keller A, Aren O, Csollak M, Albert I, Barrios CH, Grossi F, KrzakowskiM, Cupit L, Cihon F, DiMatteo S, Hanna N. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28(11):1835-1842.
52. BAYNEWS-The Bayer Press Server. Phase III trial of Nexavar in first-line advanced non-small cell lung cancer does not meet primary endpoint of overall survival. Retrieved July 13, 2010, fromhttp://www.press.bayer.com/baynews/ baynews.nsf/id/ EC452AB645C9D5BFC1257742001E3E13?Open&ccm =001
53. Schiller JH, Lee JW, Hanna NH, Traynor AM, Carbone DP. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J ClinOncol 2008;26(15S):Abstract 8014.
54. Blumenschein GR Jr., Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009;27(26):4274-4280.
55. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26(4):650-656. (Pubitemid 351264362)
56. Novello S, ScagliottiGV, Rosell R, Socinski MA, Brahmer J,Atkins J, Pallares C, Burgess R, Tye L, Selaru P,Wang E, Chao R, Govindan R. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009;101(9):1543-1548.
57. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68(12):4774-4782.
58. Roth GJ, Heckel A, Colbatzky F, Handschuh S, Kley J, Lehmann- Lintz T, Lotz R, Tontsch-Grunt U, Walter R, Hilberg F. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6- methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem 2009;52(14):4466-4480.
59. Ellis PM, Kaiser R, Zhao Y, Stopfer P, Gyorffy S, Hanna N. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated nonsmall cell lung cancer patients. Clin Cancer Res 2010;16(10): 2881-2889.
60. Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Stopfer P, von Pawel J. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011;22(6):1374-1381.
61. Nikolinakos P, Heymach JV. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracicmalignancies. J Thorac Oncol 2008;3(6 Suppl. 2):S131-S134. (Pubitemid 351786743)
62. GossGD, ArnoldA, Shepherd FA,DediuM, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 study. J Clin Oncol 2010;28(1):49-55.
63. Gadgeel SM, Wozniak A, Edelman MJ, Valdivieso M, Heilbrun L, Venkatramanamoorthy R, Shields A, LoRusso P, Hackstock D, Ruckdeschel J. Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). J ClinOncol 2009;27(15S):Abstract e19007.
64. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M. Pharmacokineticpharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007; 6(7):2012-2021. (Pubitemid 47052491)
65. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, Kumar S, Kumar R, Pandite LN, Hideshima T, Chauhan D, Anderson KC. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A 2006; 103(51):19478-19483. (Pubitemid 46026056)
66. Altorki N, Lane ME, Bauer T, Lee PC, GuarinoMJ, Pass H, Felip E, Peylan-Ramu N, Gurpide A, Grannis FW, Mitchell JD, Tachdjian S, Swann RS, Huff A, Roychowdhury DF, Reeves A, Ottesen LH, YankelevitzDF. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patientswith stage I/II resectable non-small-cell lung cancer. J Clin Oncol 2010;28(19):3131-3137.
67. Elice F, Rodeghiero F, Falanga A, Rickles FR. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol 2009;22(1):115-128.
68. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in patientswith cancer receiving antiangiogenesis agents. J Clin Oncol 2009;27(29):4865-4873.
69. Snider KL, Maitland ML. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target Oncol 2009;4(2):67-76.
70. Roodhart JM, Langenberg MH, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 2008;3(2):132-143.
71. Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, Yuan J, Hefner C, Chartier C, Lee JS, Jiang S, Nayak NR, Kuypers FA, Ma L, Sundram U, Wu G, Garcia JA, Schrier SL,Maher JJ, Johnson RS, Yancopoulos GD,Mulligan RC, Kuo CJ. VEGFmodulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006;12(7):793-800. (Pubitemid 44050069)
72. Hesser BA, Liang XH, Camenisch G, Yang S, Lewin DA, Scheller R, Ferrara N, Gerber HP. Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood 2004;104(1):149-158. (Pubitemid 38879851)
73. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: a review. Eur J Cancer 2006;42(18):3127-3139. (Pubitemid 44869016)
74. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96(12): 1788-1795. (Pubitemid 46912024)
75. Saif MW, Ramos J, Knisely J. Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer. JOP 2008;9(6):744-747.
76. Chung C, Dawson LA, Joshua AM, Brade AM. Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anticancer Drugs 2010;21(2): 206-209.
77. Tol J, Cats A, Mol L, Koopman M, Bos MM, van der Hoeven JJ, Antonini NF, van Krieken JH, Punt CJ. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs 2008;26(4):393-397.
78. Heinzerling JH, Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 2006;63(5):334-337. (Pubitemid 44340939)
79. Schellhaas E, Loddenkemper C, Schmittel A, Buhr HJ, Pohlen U. Bowel perforationinnon-small cell lung cancer after bevacizumab therapy. Invest New Drugs 2009;27(2):184-187.
80. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007;105(1):3-6. (Pubitemid 46441477)
81. Dayton MT, Kleckner SC, Brown DK. Peptic ulcer perforation associated with steroid use. Arch Surg 1987;122(3):376-380. (Pubitemid 17032728)
82. Torosian MH, Turnbull AD. Emergency laparotomy for spontaneous intestinal and colonic perforations in cancer patients receiving corticosteroids and chemotherapy. J Clin Oncol 1988;6(2):291-296. (Pubitemid 18065933)
83. Power DG, Kemeny NE. Nasal septum perforation and bevacizumab. Med Oncol 2011;28(1):89-93.
84. Mailliez A, Baldini C, Van JT, Servent V, Mallet Y, Bonneterre J. Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients. Br J Cancer 2010;103(6): 772-775.
85. Ramiscal JA, Jatoi A. Bevacizumab-induced nasal septal perforation: incidence of symptomatic, confirmed event(s) in colorectal cancer patients. Acta Oncol 2011;50(4):578-581.
86. Shord SS, Bressler LR, Tierney LA, Cuellar S, George A. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm 2009;66(11): 999-1013.
87. Ko J, Ross J, Awad H, Hurwitz H, Klitzman B. The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice. J Surg Res 2005;129(2):251-259. (Pubitemid 41797060)
88. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010;23(5):460-468.
89. Launay-Vacher V, Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 2009;20(1):81-82.
90. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O'Dwyer PJ. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006;24(9):1363-1369. (Pubitemid 46621999)
91. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 2007;50(2):203-218. (Pubitemid 47095077)
92. Gurevich F, PerazellaMA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 2009;122(4):322-328.
93. Advani A, Kelly DJ, Advani SL, Cox AJ, Thai K, Zhang Y, White KE, Gow RM, Marshall SM, Steer BM, Marsden PA, Rakoczy PE, Gilbert RE. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci U S A 2007;104(36):14448-14453. (Pubitemid 350003281)
94. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358(11):1129-1136. (Pubitemid 351398487)
95. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-799. (Pubitemid 46224178)
96. Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, Massard C, Armand JP, Soria JC. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.Nat Clin PractOncol 2008;5(5):268-278. (Pubitemid 351594143)
97. Votrient (Pazopanib). Package Insert (Revised April 2010). Research Triangle Park, NC: GlaxoSmithKline, 2010.
98. Herbst RS. Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clin Lung Cancer 2006;8(Suppl. 1):S23-S30.